Arc Bio Communications is a UK-based strategic communications consultancy specializing in the pharmaceutical and biotech sectors. The firm operates at the intersection of science, business, and public policy, aiming to maximize the impact of client innovations through intelligent communication strategies and stakeholder engagement. Arc Bio has positioned itself as a partner to both large and emerging pharma and biotech firms, providing messaging clarity around complex regulatory changes and industry narratives, particularly within the European Union.
Since its EU Transparency Register accreditation on February 23, 2023, Arc Bio Communications has focused on legislative and regulatory priorities such as the European Health Data Space (EHDS) and reforms to the EU’s pharmaceuticals framework. Its services span the drafting of strategic messaging, the creation of internal guidance regarding EU directives, and supporting panel discussions and position briefs related to pharmaceutical legislation and health data initiatives. With a base in London, the firm aligns its activities to support innovations in healthcare, public health, and industry interests at multiple levels—global, European, national, and sub-national.
The consultancy’s approach combines management consulting discipline, robust scientific expertise, and creative communication tactics to drive stakeholder belief, engagement, and actionable outcomes. Arc Bio also has a clear emphasis on digital communication platforms, adapting lobbying strategies for the digital age and seeking to elevate client voices efficiently in public policy debates around healthcare, data, and innovative therapies.
